Evaluation of bovine respiratory syncytial virus (BRSV) and bovine herpesvirus (BHV) specific antibody responses between heterologous and homologous prime-boost vaccinated western Canadian beef calves.

Bovine respiratory disease (BRD) is an economically important cause of morbidity and mortality in beef calves. Control of BRD is most often addressed through "homologous" vaccination utilizing the same injectable modified-live viral (MLV) vaccine for both priming and boosting. Heterologous prime-boosting uses different routes and antigenic forms for priming and boosting. Three vaccine protocols were compared: an injectable (IJ) MLV (IJ-MLV) group (IJ-MLV priming at ~48 days and boosted with IJ-MLV at weaning), intranasal (IN) MLV (IN-MLV) group (intranasal priming with MLV at ~24 hours, boosted twice with an IJ-MLV), and intranasal killed viral (IN-KV) group (primed with an IN-MLV at ~24 hours, boosted twice with an IJ-KV). Serum antibody concentrations determined by enzyme-linked immunosorbent assays (ELISAs) were compared and the IN-KV group had significantly higher BRSV-specific antibody concentrations after boosting compared with the 2 homologous groups. No differences in BHV-specific antibody concentrations were observed between any of the groups. Copyright and/or publishing rights held by the Canadian Veterinary Medical Association.